Meldonium Orotate Cardioprotection in Myocardial Infarction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, such as myocardial infarction and arrhythmia, do not fully leverage the cardioprotective properties of Meldonium, particularly in terms of its salt forms, which lack documented efficacy.
Innovation Solution
Meldonium orotate is introduced as a more stable and effective form, demonstrating cardioprotective effects in myocardial infarction models and reducing fatal outcomes in acute arrhythmia, surpassing the efficacy of Meldonium dihydrate and orotic acid alone.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Meldonium dihydrate is used for treating cardiovascular diseases, then cardioprotective effects are achieved, but the treatment efficacy is limited compared to salt forms
Solution Approach 1:
The patent applies parameter changes by transforming Meldonium from its dihydrate form into various salt forms (orotate, ascorbate, nicotinates, etc.). This chemical parameter transformation enhances the cardioprotective efficacy while maintaining the core mechanism of action. The salt forms demonstrate superior treatment effectiveness compared to the dihydrate form, resolving the contradiction between limited efficacy and potential for improved formulations.
2Reliability
If conventional treatments for myocardial infarction and arrhythmia are used, then standard care is provided, but cardioprotective properties of Meldonium are not fully leveraged
Solution Approach 1:
The patent transforms conventional Meldonium dihydrate into enhanced salt forms with improved cardioprotective properties. This parameter change in chemical structure translates to superior clinical efficacy in treating myocardial infarction and arrhythmia, fully leveraging and enhancing the cardioprotective potential beyond standard care.
Solution Approach 2:
The patent creates composite pharmaceutical formulations by combining Meldonium with various counterions to form salt compounds. These composite materials (Meldonium orotate, Meldonium ascorbate, etc.) exhibit enhanced therapeutic effects compared to the parent compound alone, resolving the contradiction between standard treatment and optimized therapy.
3Reliability
If Meldonium orotate is used instead of Meldonium dihydrate, then treatment efficacy is enhanced, but the formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by selecting specific counterions (orotate, ascorbate, nicotinates) that enhance Meldonium's efficacy. While this creates multiple possible formulations, each individual salt form maintains a straightforward chemical structure and manufacturing process, balancing enhanced efficacy with manageable formulation complexity.
Data Source
AI summary
The present invention relates to highly effective treatment of cardiovascular diseases with 3-(2,2,2-trimethylhydrazinium)propionate orotate.